PolarityTE, Inc. announced the appointment of Matt Kemp as Chief Commercial Officer.

Mr. Kemp will be integral in leading efforts as SkinTE™ moves toward a full national launch and in bringing other PolarityTE pipeline technologies and core "TE" products to market worldwide.

With nearly 20 years of leadership experience, Mr. Kemp has an extensive record of driving profitable growth in both large and small biotech, medical device and pharmaceutical companies. He most recently served as Chief Commercial Officer at Dendreon Pharmaceuticals, a biotechnology company whose first product is an autologous immunotherapy for the treatment of advanced prostate cancer made from a patient's own immune cells. While at Dendreon, Mr. Kemp helped champion a complete turnaround and the execution of a successful commercial strategy with the novel autologous cellular immunotherapy. Dendreon went from a net negative business to returning three consecutive years of $100+ million in profit during his tenure with the company. Mr. Kemp has also held commercial leadership positions at Zimmer Biomet, Allergan and AbbVie across a variety of technologies, products and markets.

 "We at PolarityTE are incredibly excited to have Matt join the rapidly growing PolarityTE family and have him lead the Company's commercial evolution. With his wealth of knowledge, leadership experience and commercialization strategies in advanced product lines, new markets and the development of previously unseen technologies, I believe he is more than equipped to bring this novel and innovative technology platform forward—in a way never seen before," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.

"PolarityTE is leading the charge in realizing the full potential of regenerative medicine, and I am delighted to join the leadership team at this critical and exciting time for the Company," said Matt Kemp, Chief Commercial Officer of PolarityTE. He continued, "I look forward to building and leading the commercial team that will take PolarityTE to the next level of growth and deliver on the Company's mission to bring innovative therapies to market that will improve patients' lives."